SEARCH

SEARCH BY CITATION

References

  • 1
    European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 101153.
  • 2
    Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 256072.
  • 3
    Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 310.
  • 4
    Mattes RD, Donnelly D. Relative contributions of dietary sodium sources. J Am Coll Nutr 1991; 10: 38393.
  • 5
    Melander O, Frandsen E, Groop L, Hulthen UL. Plasma ProANP(1–30) reflects salt sensitivity in subjects with heredity for hypertension. Hypertension 2002; 39: 9969.
  • 6
    Thibault G, Garcia R, Gutkowska J et al. The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. Biochem J 1987; 241: 26572.
  • 7
    Vesely DL. Atrial natriuretic hormones originating from the N-terminus of the atrial natriuretic factor prohormone. Clin Exp Pharmacol Physiol 1995; 22: 10814.
  • 8
    Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiological role for proANP-(1–30) in the regulation of renal excretion. Am J Physiol Regul Integr Comp Physiol 2001; 280: R151017.
  • 9
    Forssmann WG, Richter R, Meyer M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol 1998; 110: 33557.
  • 10
    Cusson JR, Thibault G, Kuchel O, Hamet P, Cantin M, Larochelle P. Cardiovascular, renal and endocrine responses to low doses of atrial natriuretic factor in mild essential hypertension. J Hum Hypertens 1989; 3: 8996.
  • 11
    Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000; 46: 152934.
  • 12
    de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 31622.
  • 13
    Lerman A, Gibbons RJ, Rodeheffer RJ et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 11059.
  • 14
    Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997; 36: 24655.
  • 15
    Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 124751.
  • 16
    Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997; 30: 92831.
  • 17
    Groop L, Forsblom C, Lehtovirta M et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 1996; 45: 158593.
  • 18
    Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985; 727: 1113.
  • 19
    Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 6839.
  • 20
    Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol Renal Physiol 2003; 285: F16777.
  • 21
    Newman DJ, Thakkar H, Edwards RG et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 3128.
  • 22
    Kyhse-Andersen J, Schmidt C, Nordin G et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40: 19216.
  • 23
    Mussap M, Ruzzante N, Varagnolo M, Plebani M. Quantitative automated particle-enhanced immunonephelometric assay for the routinary measurement of human cystatin C. Clin Chem Lab Med 1998; 36: 85965.
  • 24
    Suzuki M, Yamamoto K, Watanabe S, Iwata T, Hamada M, Hiwada K. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. Am J Med 2000; 108: 62733.
  • 25
    Yamamoto K, Burnett JC, Jougasaki M et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 98894.
  • 26
    Luchner A, Burnett JC, Jougasaki M et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000; 18: 11218.
  • 27
    Qi W, Mathisen P, Kjekshus J et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 72532.
  • 28
    de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31: 718.
  • 29
    Melander O, Frandsen E, Groop L, Hulthen UL. No evidence of a relation between 11β-hydroxysteroid dehydrogenase type 2 activity and salt sensitivity. Am J Hypertens 2003; 16: 72933.
  • 30
    Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002; 252: 4309.
  • 31
    Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5: 599606.
  • 32
    Wang TJ, Larson MG, Levy D et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 2548.
  • 33
    Vesely DL, Gower WR, Jr, Dietz JR et al. Elevated atrial natriuretic peptides and early renal failure in type 2 diabetic Goto-Kakizaki rats. Metabolism 1999; 48: 7718
  • 34
    Shin SJ, Lee YJ, Hsiao PJ, Tsai JH. Increased urinary atrial natriuretic peptide-like immunoreactivity excretion but decreased plasma atrial natriuretic peptide concentration in patients with hyperosmolar-hyperglycemic nonketotic syndrome. Diabetes Care 1999; 22: 11815.
  • 35
    Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm Metab Res 2002; 34: 26570.
  • 36
    Yano Y, Ura H, Gabazza EC et al. Circulating levels of 7 S domain of type IV collagen and atrial natriuretic peptide in normotensive type 2 diabetic patients with or without retinopathy. Horm Metab Res 1998; 30: 1037.
  • 37
    Yano Y, Gabazza EC, Katsuki A et al. Plasma levels of natriuretic peptides are correlated with renin activity in normotensive type 2 diabetic patients. Diabetes Care 2000; 23: 18535.
  • 38
    Chattington PD, Anderson JV, Rees LH, Leese GP, Peters JR, Vora JP. Atrial natriuretic peptide in type 2 diabetes mellitus: response to a physiological mixed meal and relationship to renal function. Diabet Med 1998; 15: 3759.
  • 39
    Kohno M, Yasunari K, Murakawa K, Kanayama Y, Matsuura T, Takeda T. Effects of high-sodium and low-sodium intake on circulating atrial natriuretic peptides in salt-sensitive patients with systemic hypertension. Am J Cardiol 1987; 59: 12123.
  • 40
    Gerdts E, Myking OL, Omvik P. Salt sensitive essential hypertension evaluated by 24 hour ambulatory blood pressure. Blood Press 1994; 3: 37580.
  • 41
    McKnight JA, Roberts G, Sheridan B, Atkinson AB. The effect of low and high sodium diets on plasma atrial natriuretic factor, the renin-aldosterone system and blood pressure in subjects with essential hypertension. Clin Endocrinol 1994; 40: 737.
  • 42
    Ferri C, Bellini C, Carlomagno A, Perrone A, Santucci A. Urinary kallikrein and salt sensitivity in essential hypertensive males. Kidney Int 1994; 46: 7808.
  • 43
    de la Sierra A, Lluch MM, Coca A et al. Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients. Clin Sci 1996; 91: 15561.
  • 44
    Campese VM, Tawadrous M, Bigazzi R et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension 1996; 28: 33540.
  • 45
    Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 93742.